Lynparza extends progression-free survival in gBRCAm metastatic pancreatic cancer

pharmafile | February 26, 2019 | News story | Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza, pharma 

AstraZeneca and MSD have lifted the curtain on new Phase 3 data for Lynparza (olaparib), confirming that the drug generated a “statistically-significant and clinically-meaningful improvement” in progression-free survival (PFS) compared to placebo as a first-line maintenance monotherapy in germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer in patients whose disease has not progressed on platinum-based chemotherapy.

According to the pair, the data make Lynparza the first PARP inhibitor to demonstrate benefit in this indication at Phase 3.

“This is the first positive Phase 3 trial of any PARP inhibitor in germline BRCA-mutated metastatic pancreatic cancer, a devastating disease with critical unmet need,” commented José Baselga, Executive Vice President, Research and Development, Oncology at AstraZeneca. “The results of POLO provide further evidence of the clinical benefit of Lynparza across a variety of BRCA-mutated tumour types. We will discuss these results with global health authorities as soon as possible.”

Roy Baynes, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer at MSD added: “Trials like POLO demonstrate the shared commitment of MSD and AstraZeneca to assess treatments for difficult-to-treat cancers. The clinically-meaningful results of this trial potentially support the value of testing for germline BRCA mutations in patients with metastatic pancreatic cancer.”

The pair confirmed that the full findings from the study will be presented at an upcoming medical meeting.

Matt Fellows

Related Content


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

Servier and Aitia enter into R&D collaboration for pancreatic cancer Digital Twins

French pharmaceutical company Servier and US-based Causal AI and Digital Twins company Aitia have announced …

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso …

Latest content